In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 10, 2005, Pages 4413-4417

  Wexler, Hannah M ^a,b,c   Engel, Adrian E ^a   Glass, Daniel ^a   Li, Calida ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Wadsworth Anaerobe Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; DORIPENEM; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; MEROPENEM;

ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; CLOSTRIDIUM DIFFICILE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BACTERIA, ANAEROBIC; BETA-LACTAMS; CARBAPENEMS; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; THIENAMYCINS;

EID: 25844474742     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.10.4413-4417.2005     Document Type: Article

References (20)

1. Bandoh, K., K. Ueno, K. Watanabe, and N. Kato. 1993. Susceptibility patterns and resistance to imipenem in the Bacteroides fragilis group species in Japan: a 4-year study. Clin. Infect. Dis. 16(Suppl. 4):s382-s386.
2. Edwards, R., and P. N. Read. 2000. Expression of the carbapenemase gene (cfiA) in Bacteroides fragilis. J. Antimicrob. Chemother. 46:1009-1012.
3. Gimeno, C., D. Navarro, F. Savall, E. Millas, M. A. Farga, J. Garau, R. Cisterna, and J. Garcia-de-Lomas. 1996. Relationship between outer membrane protein profiles and resistance to ceftazidime, imipenem, and ciprofloxacin in Pseudomonas aeruginosa isolates from bacteremic patients. Eur. J. Clin. Microbiol. Infect. Dis. 15:82-85.
4. Goldstein, E. J., D. M. Citron, M. C. Vreni, Y. Warren, and K. L. Tyrrell. 2000. Comparative in vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections. Antimicrob. Agents Chemother. 44:2389-2394.
5. Jousimies-Somer, H., P. Summanen, D. M. Citron, E. J. Baron, H. M. Wexler, and S. M. Finegold. 2002. Wadsworth-KTL anaerobic bacteriology manual. Star Publishing Company, Belmont, Calif.
6. Mikamo, H., K. Izumi, Y. X. Hua, Y. Hayasaki, Y. Sato, and T. Tamaya. 2000. In vitro and in vivo antibacterial activities of a new injectable carbapenem, S-4661, against gynaecological pathogens. J. Antimicrob. Chemother. 46:471-474.
7. Mori, M., M. Hikida, T. Nishihara, T. Nasu, and S. Mitsuhashi. 1996. Comparative stability of carbapenem and pcnem antibiotics to human recombinant dehydropeptidase-I. J. Antimicrob. Chemother. 37:1034-1036.
8. National Committee for Clinical Laboratory Standards. 2003. Methods for antimicrobial susceptibility testing of anaerobic bacteria: approved standard, 6th ed. NCCLS document M11-A6. NCCLS, Wayne, Pa.
9. Nomura, S., and A. Nagayama. 2002. In vitro antibacterial activity of S-4661, a new parenteral carbapenem, against urological pathogens isolated from patients with complicated urinary tract infections. J. Chemother. 14:155-160.
10. Ochs, M. M., M. Bains, and R. E. Hancock. 2000. Role of putative loops 2 and 3 in imipenem passage through the specific porin OprD of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44:1983-1985.
11. Okamoto, K., N. Gotoh, and T. Nishino. 2001. Pseudomonas aeruginosa reveals high intrinsic resistance to penem antibiotics: penem resistance mechanisms and their interplay. Antimicrob. Agents Chemother. 45:1964-1971.
12. Pfaller, M. A., and R. N. Jones. 1997. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide. Diagn. Microbiol. Infect. Dis. 28:157-163.
13. Podglajen, I., J. Breuil, F. Bordon, L. Gutmann, and E. Collatz. 1992. A silent carbapenemase gene in strains of Bacteroides fragilis can be expressed after a one-step mutation. FEMS Microbiol. Lett. 70:21-29.
14. Summanen, P., H. M. Wexler, and S. M. Finegold. 1992. Antimicrobial susceptibility testing of Bilophila wadsworthia by using triphenyltetrazolium chloride to facilitate endpoint determination. Antimicrob. Agents Chemother. 36:1658-1664.
15. Summanen, P., H. M. Wexler, K. W. Lee, S. Becker, M. Garcia, and S. M. Finegold. 1993. The morphological response of Bilophila wadsworthia to imipenem: correlation with the properties of penicillin-binding proteins. Antimicrob. Agents Chemother. 37:2638-2644.
16. Tanaka-Bandoh, K., N. Kato, K. Watanabe, and K. Ueno. 1995. Antibiotic susceptibility profiles of Bacteroides fragilis and Bacteroides thetaiotaomicron in Japan from 1990 to 1992. Clin. Infect. Dis. 20(Suppl. 2):S352-S355.
17. Tsuji, M., Y. Ishii, A. Ohno, S. Miyazaki, and K. Yamaguchi. 1998. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antiinicrob. Agents Chemother. 42:94-99.
18. Watanabe, A., H. Takahashi, T. Kikuchi, T. Kobayashi, K. Gomi, S. Fujimura, Y. Tokue, and T. Nukiwa. 2000. Comparative in vitro activity of S-4661, a new parenteral carbapenem, and other antimicrobial agents against respiratory pathogens. Chemotherapy 46:184-187.
19. Wexler, H. M., E. Molitoris, F. Jashnian, and S. M. Finegold. 1991. Comparison of spiral gradient with conventional agar dilution for susceptibility testing of anaerobic bacteria. Antimicrob. Agents Chemother. 35:1196-1202.
20. Wexler, H. M., E. Molitoris, P. R. Murray, J. Washington, R. J. Zabransky, P. H. Edelstein, and S. M. Finegold. 1996. Comparison of spiral gradient endpoint and agar dilution methods for susceptibility testing of anaerobic bacteria: a multilaboratory collaborative evaluation. J. Clin. Microbiol. 34: 170-174.